A Z Rohatiner
Overview
Explore the profile of A Z Rohatiner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
773
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dalley C, Rohatiner A, Bradburn M, Lillington D, Carter M, Slater S, et al.
Hematology
. 2016 Jul;
6(3):163-75.
PMID: 27420122
Between 1969 and 1999, 420 patients (age > 60 years) with newly diagnosed AML were managed at St Bartholomew's Hospital (SBH), London, UK. Sixty-nine percent of patients received therapy with...
2.
Micallef I, Apostolidis J, Rohatiner A, Wiggins C, Crawley C, Foran J, et al.
Hematol J
. 2002 Mar;
1(6):367-73.
PMID: 11920216
Introduction: High-dose therapy with haematopoietic progenitor cell support has increasingly been utilised for patients with haematological malignancies. Peripheral blood is the stem cell source of choice, however, various mobilisation strategies...
3.
Bassan R, Rohatiner A, Lerede T, Di Bona E, Rambaldi A, Pogliani E, et al.
Hematol J
. 2002 Mar;
1(4):226-34.
PMID: 11920195
Introduction: The use of anthracycline antibiotics in adult acute lymphoblastic leukemia (ALL) has resulted in an improved outcome to remission induction therapy. However,the exact role of these drugs in consolidation...
4.
Foran J, Norton A, Micallef I, Taussig D, Amess J, Rohatiner A, et al.
Br J Haematol
. 2001 Sep;
114(4):881-3.
PMID: 11564080
A retrospective analysis of CD20 expression following rituximab for B-cell non-Hodgkin's lymphoma demonstrated a significant change in immunophenotype in 6/25 (24%) patients with persistent bone marrow (BM) infiltration. In three...
5.
Micallef I, Rohatiner A, Carter M, Boyle M, Slater S, Amess J, et al.
Br J Haematol
. 2001 May;
113(2):443-5.
PMID: 11380414
Between 1972 and 1988, 832 consecutive patients were treated for acute leukaemia at St. Bartholomew's Hospital; a retrospective analysis has been conducted to determine the clinical course and outcome for...
6.
Lillington D, Micallef I, CARPENTER E, Neat M, Amess J, Matthews J, et al.
J Clin Oncol
. 2001 May;
19(9):2472-81.
PMID: 11331326
Purpose: To assess whether pre-high-dose therapy (HDT)-related factors play a critical role in the development of therapy-related myelodysplasia (tMDS) or secondary acute myelogenous leukemia (sAML). Patients And Methods: Twenty-nine of...
7.
Swerdlow A, Schoemaker M, Allerton R, Horwich A, Barber J, Cunningham D, et al.
J Clin Oncol
. 2001 Mar;
19(6):1610-8.
PMID: 11250989
Purpose: To investigate the causes of the raised risk of lung cancer in patients who have had Hodgkin's disease, and in particular the relationship to treatment. Patients And Methods: A...
8.
Dalley C, Lister T, Cavenagh J, Rohatiner A
Br J Cancer
. 2001 Jan;
84(1):147.
PMID: 11139330
No abstract available.
9.
Jenner M, Micallef I, Rohatiner A, Kelsey S, Newland A, Cavenagh J
Med Oncol
. 2000 Dec;
17(4):333-6.
PMID: 11114714
A 36-year-old man underwent matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia. He developed severe hepatic veno-occlusive disease as an early post-transplant complication. Tissue plasminogen activator was initially...
10.
Rohatiner A, Bassan R, Raimondi R, Amess J, Arnott S, Personen A, et al.
Ann Oncol
. 2000 Oct;
11(8):1007-15.
PMID: 11038038
Background: Debate and controversy remain as to the optimal post-remission therapy for younger patients with acute myelogenous leukaemia (AML). The aim of this study was to evaluate high-dose treatment (HDT)...